<div style="position: relative; display: block; max-width: 100%;"><div style="padding-top: 56.25%;"><iframe src="//players.brightcove.net/4365621440001/216a41e4-093d-49b1-831c-dbf5b8ca99d9_default/index.html?videoId=5844518697001" <!-- [et_pb_line_break_holder] -->allowfullscreen <!-- [et_pb_line_break_holder] -->webkitallowfullscreen <!-- [et_pb_line_break_holder] -->mozallowfullscreen <!-- [et_pb_line_break_holder] -->allow="encrypted-media" <!-- [et_pb_line_break_holder] -->style="position: absolute; top: 0px; right: 0px; bottom: 0px; left: 0px; width: 100%; height: 100%;"></iframe></div></div>
Department of Medicine Grand Rounds
October 2, 2018
Bench to Bedside
Gregory J. Kato, MD | Bio
Professor of Medicine, Division of Hematology/Oncology
TIME CODE 0:00 -Background: “Unmet Need for Gene Therapy in Sickle Cell Disease”
Tim M. Townes, PhD | Bio
Professor Emeritus, Department of Biochemistry and Molecular Genetics
University of Alabama at Birmingham
TIME CODE 12:12 – “Modified CRISPR/Cas for Safe and Effective Sickle Gene Correction in Patient Blood Stem Cells”
